• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Placebo: It’s Good for What Ails You

Placebo: It’s Good for What Ails You

November 1, 2013
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Caroline Fisher, PhD, MD

The most studied psychiatric medication for children, and arguably the most broad-spectrum medication available, is placebo. It has proven itself repeatedly to be as good or better than a number of FDA-approved medications that are effective in adults. It has been found to be effective in up to half of pediatric patients for conditions as different as seizures and ADHD, and is well known to treat dozens of conditions. Yet, we rarely review its risks and benefits, or the unique role it plays in the treatment of children.

We know a lot about placebo effects in adults, so is it really necessary to specifically study it in children? Several meta-analyses suggest that the answer is yes. Children with epilepsy, migraines, IBS, ADHD, obsessive compulsive disorder (OCD), anxiety disorders, and major depressive disorder (MDD) all have a greater response to placebos than adults with these conditions (Rheims S et al, PLoS Med 2008;5(8):e166).

This has particular significance in MDD where arguments regarding clinical effectiveness of antidepressants rage due to the ambiguity of short clinical trials that do not show conclusive benefit of drug versus placebo. Does that mean the drug doesn’t work? Or does it mean placebo works too well?

How Well Do Children Respond to Placebo?

Children with MDD have a placebo response rate larger than that in adults and in other pediatric conditions. One pediatric MDD study estimated the average placebo response rate to be 48% (Rutherford BR et al, Am Acad Child Adolesc Psychiatry 2011;50(8):782–795). Another calculated that it was 54.3% in children under 12 and 44.9% in those age 12 to 18 (Enuck Pl et al, Pediatric Research 2013;74:1). Compare that to adults: rates of placebo response are 29.7% to 38% (Brunoni AR et al, PLoS ONE 2009;4(3): e4824; Enuck Pl et al, Pediatric Research 2013;74:1).

Placebo effects might also play a bigger role in MDD than other psychiatric conditions. The author of a review that found placebo response rates around 50% in MDD suggested that one reason for the high rate could be that interaction with the clinician unintentionally provides support and helps to increase self-esteem, which are key factors in treating depression (Cohen D et al, PLoS ONE 2008;3(7):e2632).

Interestingly, one meta-analysis (Whiteford HA, Psychological Medicine 2013;43:1569–1585) looking at waitlist trials estimated the spontaneous remission rate to be between 19% and 44% (excluding trials less than six weeks long), suggesting that the placebo response represents an actual improvement in symptoms rather than the mere passage of time.

Why Are Children More Responsive to Placebo?

Expectancy plays a large role in the placebo effect in adults, but the same might not be true for children. Studies show that the placebo effect doesn’t necessarily increase when there is a high probability of receiving an active drug (Rutherford BR et al, Am Acad Child Adolesc Psychiatry 2011;50(8):782–795). However, one study that involved exposure to pain stimulus suggested that conditioning and learning by social observation contribute significantly to placebo responses in children. In other words, seeing other children respond a certain way may make kids more likely to respond themselves (Bendetti F and Collaca L, Pain 2009;144(1–2):28–44).

Another possibility is that interactions with healthcare workers contributes to the placebo effect. One study showed that with older youths there was a correlation between the amount of time spent with clinicians and the response rate to placebo (Rutherford BR op.cit). There may be an effect due to the therapeutic alliance which is unintentionally created during a trial.

How Can Placebos Benefit Patients?

Placebos can be used to benefit patients in clinical practice. A study of children with ADHD suggests that we can “harvest” the placebo benefits without deception. Some children on the optimum dose of a stimulant had no change in symptoms when their doses were reduced by way of an active pill that was half their previous dose, plus a pill they knew was a placebo (Bodfish JW et al, J Dev Behav Pediatr 2010;31(5):369–375).

And there’s another form of placebo that physicians should be aware of. When a patient begins a treatment, it affects the thoughts, emotions and responses of doctors, family members, and friends through a process called “placebo by proxy” (Grelotti D et al, BMJ 2011;343:d4345). Parents get relief from worry, even if the drugs are nothing more than “impure placebos.” Through understanding the grip that “placebo by proxy” has on us, we can avoid it pushing us away from evidence based medicine.

CCPR’s Verdict: Placebo can be a safe and surprisingly effective treatment. We should take time to make use of the placebo effect without deception in our own practices.
Child Psychiatry
KEYWORDS natural_medications
    www.thecarlatreport.com
    Issue Date: November 1, 2013
    SUBSCRIBE NOW
    Table Of Contents
    Can Diet Really Improve Autism?
    How Can Teachers Best Help Us Identify ADHD?
    The Power of a Child’s Subjective Response to Trauma
    Probiotics: Good for the Mind?
    More Teens Smoking Flavored Little Cigars
    Nutritional Supplements in the Treatment of Childhood ADHD
    Placebo: It’s Good for What Ails You
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.